Simon Lovestone

64.7k total citations · 3 hit papers
368 papers, 21.0k citations indexed

About

Simon Lovestone is a scholar working on Physiology, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Simon Lovestone has authored 368 papers receiving a total of 21.0k indexed citations (citations by other indexed papers that have themselves been cited), including 199 papers in Physiology, 136 papers in Molecular Biology and 115 papers in Psychiatry and Mental health. Recurrent topics in Simon Lovestone's work include Alzheimer's disease research and treatments (190 papers), Dementia and Cognitive Impairment Research (105 papers) and Bioinformatics and Genomic Networks (28 papers). Simon Lovestone is often cited by papers focused on Alzheimer's disease research and treatments (190 papers), Dementia and Cognitive Impairment Research (105 papers) and Bioinformatics and Genomic Networks (28 papers). Simon Lovestone collaborates with scholars based in United Kingdom, United States and Italy. Simon Lovestone's co-authors include Richard Killick, Claudie Hooper, Bruno Vellas, Magda Tsolaki, Patrizia Mecocci, Hilkka Soininen, Iwona Kłoszewska, Andrew Simmons, John Powell and Amritpal Mudher and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Neuroscience.

In The Last Decade

Simon Lovestone

362 papers receiving 20.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The GSK3 hypothesis of Alzheimer’s disease

2007 956 citations Claudie Hooper, Richard Killick et al. Journal of Neurochemistry profile →
Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood

2012 494 citations Simon Lovestone et al. profile →
A Phase II Trial of Tideglusib in Alzheimer's Disease

2015 404 citations Simon Lovestone et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Simon Lovestone	9.5k	7.7k	5.3k	2.7k	2.7k	368	21.0k
Suzanne Craft	12.8k 1.4×	5.9k 0.8×	4.5k 0.9×	4.7k 1.7×	3.2k 1.2×	337	27.9k
Jin‐Tai Yu	8.9k 0.9×	7.2k 0.9×	4.7k 0.9×	5.3k 1.9×	2.3k 0.9×	454	23.8k
Lan Tan	9.3k 1.0×	6.6k 0.9×	5.1k 1.0×	5.5k 2.0×	2.2k 0.8×	564	24.2k
Gary W. Small	10.0k 1.1×	4.2k 0.5×	7.2k 1.4×	2.5k 0.9×	2.1k 0.8×	245	20.9k
Ralph N. Martins	15.6k 1.6×	7.1k 0.9×	8.6k 1.6×	4.0k 1.4×	2.5k 1.0×	591	29.3k
Johannes Kornhuber	7.4k 0.8×	8.7k 1.1×	4.9k 0.9×	3.1k 1.1×	5.2k 1.9×	852	26.3k
Patrizia Mecocci	7.7k 0.8×	5.8k 0.8×	4.1k 0.8×	2.8k 1.0×	1.3k 0.5×	335	19.9k
Vahram Haroutunian	7.0k 0.7×	9.7k 1.3×	3.0k 0.6×	2.7k 1.0×	6.3k 2.4×	334	21.9k
Lindsay A. Farrer	7.2k 0.8×	7.4k 1.0×	4.3k 0.8×	1.6k 0.6×	3.1k 1.2×	425	23.6k
Lars Lannfelt	14.2k 1.5×	8.4k 1.1×	3.3k 0.6×	3.1k 1.1×	2.9k 1.1×	312	20.7k

Countries citing papers authored by Simon Lovestone

Since Specialization

Citations

This map shows the geographic impact of Simon Lovestone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Lovestone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Lovestone more than expected).

Fields of papers citing papers by Simon Lovestone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Lovestone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Lovestone. The network helps show where Simon Lovestone may publish in the future.

Co-authorship network of co-authors of Simon Lovestone

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Lovestone. A scholar is included among the top collaborators of Simon Lovestone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Lovestone. Simon Lovestone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maruszak, Aleksandra, Edina Silajdžić, Hyun-Ah Lee, et al.. (2022). Predicting progression to Alzheimer’s disease with human hippocampal progenitors exposed to serum. Brain. 146(5). 2045–2058. 19 indexed citations

Hillary, Robert F., Danni A. Gadd, Daniel L. McCartney, et al.. (2022). Genome‐ and epigenome‐wide studies of plasma protein biomarkers for Alzheimer's disease implicate TBCA and TREM2 in disease risk. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 14(1). e12280–e12280. 5 indexed citations

Zhang, Yuting, Noel J. Buckley, Sebastiaan Engelborghs, et al.. (2022). Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks. Frontiers in Aging Neuroscience. 14. 1040001–1040001. 10 indexed citations

Sommerlad, Andrew, Nomi Werbeloff, Gayan Perera, et al.. (2021). Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data. International Journal of Geriatric Psychiatry. 37(1). 9 indexed citations

Martín‐Sánchez, Ana, Janet Piñero, Lara Nonell, et al.. (2021). Comorbidity between Alzheimer’s disease and major depression: a behavioural and transcriptomic characterization study in mice. Alzheimer s Research & Therapy. 13(1). 73–73. 28 indexed citations

Mårtensson, Gustav, Joana B. Pereira, Patrizia Mecocci, et al.. (2018). Stability of graph theoretical measures in structural brain networks in Alzheimer’s disease. Scientific Reports. 8(1). 11592–11592. 38 indexed citations

Koychev, Ivan, Roger N. Gunn, John T. Lawson, et al.. (2018). PET Tau and Amyloid-beta Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers (vol 60, pg 283, 2017). 63. 407–407. 1 indexed citations

Ben, Diego Dal, et al.. (2017). Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7. EJNMMI Research. 7(1). 31–31. 48 indexed citations

Nevado‐Holgado, Alejo, et al.. (2016). Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open. 6(11). e012177–e012177. 54 indexed citations

10.

Knapp, Martín, Kia‐Chong Chua, Matthew Broadbent, et al.. (2016). Predictors of care home and hospital admissions and their costs for older people with Alzheimer's disease: findings from a large London case register. BMJ Open. 6(11). e013591–e013591. 68 indexed citations

11.

Lovestone, Simon. (2014). Blood biomarkers for Alzheimer’s disease. Genome Medicine. 6(8). 65–65. 16 indexed citations

12.

Mullins, Diane, Eileen Daly, Andrew Simmons, et al.. (2013). Dementia in Down’s syndrome: an MRI comparison with Alzheimer’s disease in the general population. Journal of Neurodevelopmental Disorders. 5(1). 19–19. 29 indexed citations

13.

Sims, Rebecca, Paul Hollingworth, Valentina Moskvina, et al.. (2009). Evidence that variation in the oligodendrocyte lineage transcription factor 2 (OLIG2) gene is associated with psychosis in Alzheimer's disease. Neuroscience Letters. 461(1). 54–59. 24 indexed citations

14.

Al‐Shawi, Raya, Anne‐Sophie Hafner, Christopher Thrasivoulou, et al.. (2008). Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system (European Journal of Neuroscience (2008) 27, (2103-2114)). European Journal of Neuroscience. 28. 1940. 2 indexed citations

15.

Hooper, Claudie, Mahvash Tavassoli, J. Paul Chapple, et al.. (2006). TAp73 isoforms antagonize Notch signalling in SH‐SY5Y neuroblastomas and in primary neurones. Journal of Neurochemistry. 99(3). 989–999. 25 indexed citations

16.

Anderton, Brian, Michelle A. Utton, Diane P. Hanger, et al.. (2002). The pathological importance of microtubules and tau. Movement Disorders. 17(6). 1402–1402. 1 indexed citations

17.

Harold, Denise, T Peirce, Marian L. Hamshere, et al.. (2002). No association of polymorphisms in the chat locus with late-onset Alzheimer's disease. Neurobiology of Aging. 23(1). 1 indexed citations

18.

Lovestone, Simon. (1998). Early diagnosis and treatment of Alzheimer's disease. 1 indexed citations

19.

Kehoe, Patrick G., Julie Williams, Simon Lovestone, Gordon Wilcock, & Michael John Owen. (1996). Presenilin-1 polymorphism and Alzheimer's disease. The UK Alzheimer's Disease Collaborative Group. Journal of Psychopharmacology. 347(9009). 1 indexed citations

20.

Lovestone, Simon. (1992). Periodic Psychosis Associated with the Menstrual Cycle and Increased Blink Rate. The British Journal of Psychiatry. 161(3). 402–404. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact